African oncology government tenders: what the bid document actually asks for, and what separates a winning response from an also-ran.

Oncology tendering in Africa looks, on the surface, a lot like oncology tendering in Europe. The bid documents quote framework periods, indicative volumes, regulatory prerequisites and delivery schedules. Underneath, the mechanics are different in ways that decide whether a new entrant wins the award, loses cleanly, or wins and then hits a stock-out penalty on the first drawdown. This is a walk through those mechanics, written for a commercial lead about to respond to their first African oncology ITB.

How African oncology tenders are structured — and where they diverge from EU frameworks.

Start with the shape of the instrument. African oncology procurement uses three dominant structures, and the bid document will tell you which one you are reading if you look for the right language.

• Indicative-volume framework. A 2-3 year framework with estimated annual volumes, drawn against as the country budget releases. No take-or-pay. Most public-sector African oncology tenders sit here. The indicative volume is a planning figure, not a guaranteed off-take.
• Awarded-volume contract. Specified volumes the buyer actually commits to. Rare in oncology; more common in first-line antibiotic and antimalarial procurement where Global Fund co-financing underwrites the commitment.
• Emergency top-up. Ad-hoc orders outside the framework when real demand overshoots projection, or when the incumbent supplier fails a drawdown. The emergency top-up route is how new bidders sometimes enter a market — a single delivered emergency order becomes the credential for the next framework tender.

The award logic on top of the structure is equally important. Single-source awards go to one winner — common when only one supplier holds the full regulatory file. Dual- or multi-source awards split the framework across two or three suppliers on pre-defined percentages, common for ARVs and starting to appear in oncology as central medical stores de-risk single-supplier dependence. Read the bid cover sheet carefully: it will say which.

The EU tender reader's instinct — that "indicative" roughly equals committed — does not carry over. An indicative-volume framework in Nairobi or Lagos genuinely means up to that volume, as budget permits. The financial planning on your side has to allow for the lower end of the band.

The buyers — public central medical stores, private hospital groups and the donor layer.

African oncology procurement splits across three buyer types, and a serious bid strategy tracks all three because the regulatory dossier is the same and the commercial terms differ.

Public sector — the central medical stores

The public route runs from the Ministry of Health to a central medical store, then to public hospital pharmacies. The key counterparties:

• Nigeria: Federal Ministry of Health (FMoH), with state ministries and the National Hospital running their own supplementary procurement.
• Kenya: KEMSA (Kenya Medical Supplies Authority) — the central procurement agency.
• Uganda: NMS (National Medical Stores).
• Tanzania: MSD (Medical Stores Department).
• Ghana: CMS (Central Medical Stores) under the Ministry of Health.
• Ethiopia: EPSS (Ethiopian Pharmaceutical Supply Service).
• South Africa: Provincial Departments of Health run tenders under national framework contracts, with SAHPRA as the registering regulator.

Private sector — the hospital-group formularies

The private-sector tender layer is growing quickly and is where the monoclonal biosimilar and supportive-care business lives. Aga Khan Health Services, Nairobi Hospital, Gertrude's Children's Hospital and MP Shah run consolidated East-African tenders; Reddington and Lagoon groups do the equivalent in Nigeria; Netcare, Mediclinic SA and Life Healthcare run the South African private chains. These bids are smaller in absolute volume than the public tenders but typically pay faster, in USD, and accept a wider molecule list including cold-chain biosimilars.

Donor-funded — the narrow layer

Oncology sits outside the core mandate of Global Fund and PEPFAR, which fund HIV, TB and malaria. UNICEF occasionally procures paediatric oncology in low-income settings. The WHO Access to Cancer Medicines Initiative (ATOM) and the Union for International Cancer Control run programme-level procurement. If a tender cover sheet references "donor-funded lot," it is almost never Global Fund for oncology — read the funding clause.

The regulatory and quality bar: WHO-GMP first, national dossier second.

African oncology tenders are dossier-gated. The bid-day file is roughly the same across the six major buyers, with country-specific wrappers on top.

1. WHO-GMP certificate of the manufacturing site. This is the primary quality credential. An EU-GMP certificate on its own is not a substitute — African regulators want the WHO-GMP. If the site holds both, submit both.
2. National product registration. NAFDAC in Nigeria, PPB in Kenya, SAHPRA in South Africa, FDA in Ghana, EFDA in Ethiopia, TMDA in Tanzania. Registration is the ticket to the tender. A handful of emergency procurements accept a valid CoPP pending registration, but these are exceptions.
3. WHO-PQ where available. The WHO Prequalification list for oncology is narrow — a subset of imatinib, paclitaxel, tamoxifen and a few others. Where PQ exists, several central medical stores score it, and a PQ-listed product typically clears faster. Where PQ does not exist for a molecule, the national dossier carries the whole weight.
4. Batch-specific Certificate of Analysis. Bid day wants sample batch CoAs — not a template. A generic product CoA is a common bid failure.
5. Pharmacovigilance commitment. A named local PV contact, an adverse-event reporting workflow to the national regulator, and a written PV plan. This is frequently a separate bid section.
6. Stability data on Zone IVb conditions. Sub-Saharan Africa is Zone IVb (30°C / 75% RH). Stability data generated on Zone II conditions alone will be challenged — run the IVb study before the bid, not after.

For the full documentation picture and how the Indian export chain feeds into these requirements, see our primer on WHO-GMP, CDSCO and the paper trail that gets your container cleared.

The molecule list and the cold-chain split.

Most African public-sector oncology tenders draw from a recognisable list. The workhorse cytotoxics and supportive-care molecules are ambient-stable (15-25°C); a small subset of biosimilars and growth factors are 2-8°C and tend to sit in the private-sector layer rather than public procurement in lower-income countries.

Ambient (15-25°C) — the public-sector core

• Solid tumours: paclitaxel, docetaxel, gemcitabine.
• Colorectal: 5-fluorouracil, capecitabine, oxaliplatin, irinotecan.
• Haematology and paediatric ALL: cyclophosphamide, doxorubicin, vincristine, methotrexate.
• Multi-indication platinums: cisplatin, carboplatin.
• Targeted oral: imatinib (CML).
• Endocrine: tamoxifen, letrozole, anastrozole, bicalutamide.
• Supportive care: ondansetron, granisetron, dexamethasone.

Cold-chain (2-8°C) — mostly private-sector

• G-CSF: filgrastim, pegfilgrastim.
• Monoclonal biosimilars: rituximab, trastuzumab, bevacizumab — where the market supports private payment or a referral hospital has built a biosimilar formulary.

Cold-chain oncology into Africa shares the same lane mechanics as cold-chain biologicals generally — validated 2-8°C shippers, logger data at destination, and a written excursion protocol. Our 72-hour cold chain to Lagos piece covers the dwell-time realities on the Mumbai-to-Lagos, Accra and Nairobi lanes.

A practical planning point: the public tender workload is almost entirely ambient cytotoxics. If the bid document asks for "temperature-controlled transport" on an ambient SKU, that usually means 15-25°C-controlled, not 2-8°C — a different (and cheaper) lane. Read the Storage Conditions clause before pricing.

Commercial terms — USD pricing, payment security, framework length.

The commercial envelope of an African oncology tender typically includes:

• Currency. USD or EUR invoicing for most public tenders. Some use local currency with USD indexation to handle devaluation risk. Private-group tenders are usually USD.
• Payment. Letter of Credit, sovereign guarantee, or direct government payment 30-90 days after delivery and acceptance. Nigerian FMoH payments frequently route through a CBN-backed mechanism; KEMSA and NMS pay on delivery-acceptance with statutory windows. South African provincial tenders pay through the PFMA regime.
• Term. 2-3 year frameworks with option-year extensions are standard. The framework does not lock pricing — the bid typically allows annual price review tied to a published index or a re-tender clause.
• Delivery cadence. Quarterly or bi-monthly drawdowns against the framework. The bid will ask for the delivery schedule as part of the response — a generic "delivery as per order" answer is scored down against a specific quarterly schedule with named ports and lead times.
• Stock-out penalties. Range from liquidated damages per day of shortage to disqualification from the next tender cycle. Read the penalty clause before pricing — an aggressive price that fails to hold the inventory buffer ends up costing more than the next-ranked bid.
• Manufacturing capacity commitment. Many tenders require a letter from the manufacturer confirming reservation of production capacity for the framework volume. The letter is non-trivial to source if the manufacturer is a third-party site — structure the supply agreement upstream before the bid.

What separates a winning bid from an also-ran.

After walking dozens of African oncology bid responses through to award or loss, the pattern on the winning side is consistent. A serious bid carries all six of the following, on bid day, cross-referenced:

1. A complete regulatory pack. WHO-GMP certificate, CoPP (dated inside the validity window), national product registration evidence, sample batch CoAs, the PV plan, and the stability data. Not one of them "to follow."
2. Pricing that reflects real landed cost. Experienced procurement leads at KEMSA, NMS and FMoH see through aspirational FOB pricing that won't survive delivery. A 20% underbid that collapses on the first drawdown gets the supplier disqualified from the next cycle.
3. A named local partner with import-agent status. Not a distributor, not a sales agent — the named importer of record, with valid licence and the regulatory credentials in-country. This is a frequent bid failure: the named partner turns out to lack the import agency, and customs clearance stalls.
4. A post-award delivery plan with specifics. Named port of entry (Apapa, Mombasa, Dar es Salaam, Tema, Durban), named customs-clearance partner, named destination warehouse, named transport lane. "Quarterly delivery" is not a plan — dates and ports are.
5. A pharmacovigilance plan with a named local contact. Often a separate bid section. The local PV contact must be reachable, authorised to file AE reports to the national regulator, and named in writing.
6. A stock-out mitigation plan. Named secondary manufacturing site, buffer-stock arrangement at a regional warehouse, or a documented expediting protocol. The buyer wants to see that a single-point failure does not break the framework.

The bids that win are the bids where every one of these is answered by a document that already exists, not a promise that it will exist.

The six bid failures we see most often.

The failure modes repeat. Most are avoidable if the bid team reads the document twice.

1. Reading the bid fast and missing the batch-CoA ask. "Batch CoA" in the bid document means sample batch CoAs — an actual pair of released-lot reports — not a product specification template. Bids that submit a generic product CoA are scored down or rejected at technical evaluation.
2. Naming the wrong local partner. A distributor without import-agent status cannot clear customs, even if it can sell. The named partner on the bid must hold the import licence with the relevant regulator.
3. Pricing too aggressively. An underbid of 20-30% against the second-ranked bidder triggers a value-for-money review. If the buyer cannot see how the price delivers the specified quality plus the logistics, the bid is disqualified on viability.
4. Skipping the pharmacovigilance section. The PV plan is frequently treated as boilerplate and is in fact scored. A bid with a thin or missing PV plan loses points against a competitor who has named the local PV officer and attached the AE-reporting SOP.
5. Submitting EU-GMP only. The tender asks for WHO-GMP. An EU-GMP certificate alone is not enough. If the site is dual-certified, submit both — but the WHO-GMP must be there.
6. Underspecifying the post-award delivery schedule. "Quarterly delivery" is not a plan. The bid expects specific months, specific ports, specific transit times, and a named clearance partner. Vague answers lose to specific answers on equal price.

FAQ

Does Global Fund procure oncology medicines for African countries?

No. Global Fund's mandate is HIV, TB and malaria — oncology is outside its procurement scope. PEPFAR is similarly scoped to HIV. A narrow donor layer exists through UNICEF for paediatric oncology in low-income settings, the WHO Access to Cancer Medicines Initiative (ATOM), and the Union for International Cancer Control. For most African oncology procurement, the funding sits with the national Ministry of Health or the central medical store's own budget line — and increasingly with private hospital groups running consolidated formulary tenders.

Is WHO Prequalification (WHO-PQ) mandatory for an African oncology tender?

No, but where a WHO-PQ listing exists for the molecule, central medical stores typically score it and a PQ-listed product clears technical evaluation faster. The practical picture: the WHO-PQ list for oncology is narrow, covering a subset of molecules. For the majority of oncology SKUs, the national product registration — NAFDAC, PPB, SAHPRA, EFDA, TMDA, Ghana FDA — does the heavy lifting. If your molecule is PQ-listed and you can afford the dossier preparation, it is worth pursuing; if not, a complete national dossier is the path.

What is the typical payment term on an African public-sector oncology tender?

Most public-sector frameworks pay 30-90 days after delivery and acceptance, denominated in USD or EUR, against a Letter of Credit, sovereign guarantee or direct ministerial payment mechanism. Nigerian FMoH payments frequently route through a CBN-backed mechanism. KEMSA and NMS pay on delivery-acceptance within statutory windows. South African provincial tenders pay under the Public Finance Management Act regime. Private hospital group tenders typically pay faster than public-sector contracts and in USD against a commercial credit line.

Can M Care help with a live African oncology tender response?

Yes. We have supplied African public-sector oncology tenders and private hospital group formularies, and we run the regulatory desk that prepares the NAFDAC, PPB, SAHPRA, EFDA and Ghana FDA dossier pack, the local-partner structuring, and the post-award delivery discipline. If you are assembling a response to an active ITB, send the bid document to the Mumbai desk and we will return a go/no-go recommendation plus a line-by-line gap list against the six bid-day requirements within 48 hours.